Cairo, Egypt — September 30, 2024 — Rameda (RMDA.CA), one of Egypt's leading pharmaceutical companies, has announced the completion of its largest acquisition to date. The company has successfully acquired a flagship diabetes treatment product, positioning itself for significant expansion in the diabetes drug market. Rameda projects that sales of the newly acquired product could reach EGP 400 million by 2025.
This acquisition is part of Rameda's broader strategy to expand its portfolio and establish a stronger presence in Egypt’s pharmaceutical sector, particularly in the fast-growing field of diabetes treatment. With Egypt facing one of the highest diabetes rates globally, the addition of this key product will enable Rameda to meet increasing patient demand while offering more affordable, high-quality medication to the local market.
Dr. Amr Morsi, CEO of Rameda, expressed confidence in the company’s ability to leverage this acquisition for further growth, noting that the deal aligns with Rameda’s commitment to addressing critical health challenges facing the country. “This is a landmark moment for us, as it positions Rameda as a key player in the treatment of diabetes, which remains a pressing health issue in Egypt,” he said.
The acquired product has consistently shown robust market performance, achieving a compound annual growth rate (CAGR) of 54% between 2020 and 2023, according to IQVIA data. The product's existing sales footprint includes over 362,000 treatment units sold in Egypt alone, further highlighting its importance in the local healthcare landscape.
Rameda has laid out ambitious plans for the future of the product, aiming to triple its market presence by expanding distribution and making the medication more accessible to underserved areas. This acquisition is part of Rameda's broader vision to establish a more comprehensive and accessible healthcare infrastructure for Egypt and beyond.
